<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04777227</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT04777227</nct_id>
  </id_info>
  <brief_title>Effectiveness of Saline Water and Lidocaine Injections for the Treatment of Intractable Plantar Keratoma</brief_title>
  <official_title>Effectiveness of Saline Water and Lidocaine Injections for the Treatment of Intractable Plantar Keratoma: A Randomised Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université du Québec à Trois-Rivières</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université du Québec à Trois-Rivières</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An intractable plantar keratoma (IPK) is a conical thickening of the epidermis' stratum&#xD;
      corneum and a common cause of foot pain which can have a significant, detrimental impact on&#xD;
      the mobility, quality of life and independence of individuals. Conservative treatments are&#xD;
      currently offered to patients with IPK, but they are unsatisfactory since they do not offer a&#xD;
      sufficient or permanent reduction of symptoms. The purpose of this study was the evaluation&#xD;
      of the feasibility, safety and effectiveness of innovative treatments for intractable plantar&#xD;
      keratoma (IPK)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 7, 2015</start_date>
  <completion_date type="Actual">September 15, 2019</completion_date>
  <primary_completion_date type="Actual">September 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in pain (visual analogue scale)</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks, 12 weeks, 6 months, 12 months</time_frame>
    <description>Patients were asked to rate their pain level during the seven previous days on the visual analogue scale (VAS). The VAS is a 10 centimeters line anchored at the beginning by &quot;no pain&quot; and at the end by &quot;worst pain imaginable&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Foot-Function-Index-Revised (FFI-R)</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks, 12 weeks, 6 months, 12 months</time_frame>
    <description>The Foot Function Index (FFI) measure the impact of foot pathology on function in terms of pain, disability and activity restriction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in size of Intractable plantar keratoma</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks, 12 weeks, 6 months, 12 months</time_frame>
    <description>IPK's length and width was measured with a millimeter scale ruler used in wound care (accuracy ± 0.1 mm). The depth was estimated with a cotton tip applicator technique measured with the same ruler</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Intractable Plantar Keratoma</condition>
  <arm_group>
    <arm_group_label>Debridement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A debridement (procedure involving cleaning and removing all hyperkeratotic tissue) was completed using a scalpel and number 15 blade, a podiatry drill and a spherical podiatry burr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Debridement with needle insertion</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>A debridement was followed by the insertion of a 27-gauge needle on a 3 mL syringe that was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side. The syringe was removed and the IPK was bandaged with a sterile gauze and medical tape.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Debridement with physiological water injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A debridement was followed by the insertion of a 27-gauge needle on a 3 mL syringe that was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side. The podiatrist pressed completely on the syringe to inject 1 mL of 0.9% sterile sodium chloride water. The syringe was removed and the IPK was bandaged with a sterile gauze and medical tape.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Debridement with lidocaine injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A debridement was followed by the insertion of a 27-gauge needle on a 3 mL syringe that was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side. The podiatrist pressed completely on the syringe to inject 1 mL of 2% lidocaine solution. The syringe was removed and the IPK was bandaged with a sterile gauze and medical tape.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine injection</intervention_name>
    <description>2% (20mg/ml) lidocaine solution</description>
    <arm_group_label>Debridement with lidocaine injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physiological water injection</intervention_name>
    <description>0.9% sterile sodium chloride water</description>
    <arm_group_label>Debridement with physiological water injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Debridement</intervention_name>
    <description>A debridement was completed using a scalpel and number 15 blade, a podiatry drill and a spherical podiatry burr.</description>
    <arm_group_label>Debridement</arm_group_label>
    <arm_group_label>Debridement with lidocaine injection</arm_group_label>
    <arm_group_label>Debridement with needle insertion</arm_group_label>
    <arm_group_label>Debridement with physiological water injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Needle insertion</intervention_name>
    <description>A 27-gauge needle on a 3 mL syringe was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side</description>
    <arm_group_label>Debridement with needle insertion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Having a painful IPK for at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ongoing pregnancy or breastfeeding&#xD;
&#xD;
          -  Severe cardiovascular or neurological disease&#xD;
&#xD;
          -  Immunosuppressed status&#xD;
&#xD;
          -  Presence of a plantar ulcer&#xD;
&#xD;
          -  Allergy to lidocaine&#xD;
&#xD;
          -  History of keloid or hypertrophic scar&#xD;
&#xD;
          -  Simultaneous painful plantar syndrome unrelated to the presence of an IPK&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Cantin, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Université du Québec à Trois-Rivières</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique podiatrique de l'Université du Québec à Trois-Rivières</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <zip>G8Z 4M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université du Québec à Trois-Rivières</investigator_affiliation>
    <investigator_full_name>Vincent Cantin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

